Evidence map›Paper›PMID 39909102›Full record

ArticleChest2025

Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United States.

Cheng Chen, Hao Xue, C Robert Horsburgh, Maryam Amour, Mark Hatherill, Michele Tameris, C Fordham von Reyn, Christiaan Rees, Ye Shen, Helen McShane and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Chest, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Cheng ChenDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, Jiangsu Province, China.
Hao XueDepartment of Chronic Communicable Diseases, Center for Disease Control and Prevention of Yancheng, Yancheng, China.
C Robert HorsburghDepartment of Epidemiology, School of Public Health, Boston University, Boston, MA; Department of Biostatistics, School of Public Health, Boston University, Boston, MA; Department of Global Health, School of Public Health, Boston University, Boston, MA.
Maryam AmourDepartment of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Mark HatherillSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM), and Department of Pathology, University of Cape Town, Cape Town, South Africa.
Michele TamerisSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM), and Department of Pathology, University of Cape Town, Cape Town, South Africa.
C Fordham von ReynDartmouth International Vaccine Initiative, Geisel School of Medicine at Dartmouth, Hanover, NH.
Christiaan ReesDartmouth International Vaccine Initiative, Geisel School of Medicine at Dartmouth, Hanover, NH; Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Ye ShenDepartment of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA.
Helen McShaneJenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, England.
Alberto L García-BasteiroCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Donglin LiuDepartment of Acute Infectious Diseases, Center for Disease Control and Prevention of Dongtai, Yancheng, China.
Yijun WangDepartment of Acute Infectious Diseases, Center for Disease Control and Prevention of Dongtai, Yancheng, China.
Ruvandhi R NathavitharanaDivision of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA.
Edward A GravissDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital Research Institute, Houston, TX.
Yan ShaoDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, Jiangsu Province, China.
Qiao LiuDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, Jiangsu Province, China.
Wei LuDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, Jiangsu Province, China.
Limei ZhuDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, Jiangsu Province, China. Electronic address: jsjkmck@163.com.
Leonardo MartinezDepartment of Epidemiology, School of Public Health, Boston University, Boston, MA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is an ongoing debate about whether clearance of Mycobacterium tuberculosis infection occurs and at what magnitude. Recent studies quantifying "uncertainty zones" of interferon-gamma release assays (IGRAs) provide a more stringent estimate of reversion. RESEARCH QUESTION: When accounting for uncertainty zones through stringent cutoffs, what are the trajectories of IGRAs results over 2 years of testing? STUDY DESIGN AND

methodsFive cohorts from South Africa, China, Tanzania, and the United States tested with an IGRA 3 or more times were followed up for stringent conversion and reversion. The annual risk of IGRA reversion was assessed following an IGRA conversion and among those with baseline positivity.

resultsA total of 26,596 IGRA measurements were taken over 13,593 years of follow-up (N

interpretationThese results suggest high annual rates of IGRA reversion, even with the use of uncertainty zones; reversion rates decreased over time from exposure and at older ages.

Indexed as

Interferon-gamma Release TestsLatent TuberculosisMycobacterium tuberculosisTuberculosisAdultAgedChinaCohort StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedSouth AfricaTanzaniaUnited Statesinterferon gamma release assayMycobacterium tuberculosisTB clearancetransmission

Identifiers

PMID39909102
PMCPMC12264344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.